Trial intelligence / Profile preview

TEG-CABG: Clopidogrel + Aspirin in Hypercoagulable CABG Patients

NCT01046942Phase 3

Key facts

Status: Unknown
Start: Nov 2008
Primary completion: May 2014
Countries: 1
Sponsor: Rigshospitalet
Modality: Small Molecules

Drugs: clopidogrel
Conditions: Graft occlusionthrombosis

Overview

Phase 3, randomised, open-label trial of clopidogrel in Graft occlusion and thrombosis (2 arms), sponsored by Rigshospitalet. Primary endpoint: Graft patency at 3 months. Status: unknown.

Design

2 arms

Study design: RandomizedOpen-label

Clopidogrel + Aspirin
Clopidogrel 75mg daily (after 300mg loading) + Aspirin 75mg daily
Aspirin Control
Aspirin 75mg daily

Endpoints

Primary

Graft patency at 3 months3 months

Secondary

Rate of other thromboembolic events and cardiovascular death3 months
Assessing coagulation profile pre- and postoperatively3 months

Beyond the preview

Go deeper on NCT01046942.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01046942.